Form SCHEDULE 13G Aquestive Therapeutics, Filed by: Bass Edward P

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Bass Edward P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,385,561.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,385,561.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,385,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: 7,876,267 shares are held by Thru Line L.P. In his capacity as the sole director and President of Thru Line GP L.L.C., which is the general partner of Thru Line L.P., Edward P. Bass ("EPB") exercises voting and dispositive power over the 7,876,267 shares held by Thru Line L.P. 1,509,294 shares are held by EPB individually.

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

THRU LINE L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,876,267.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,876,267.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,876,267.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Voting and dispositive power is exercised by Edward P. Bass in his capacity as the sole director and President of Thru Line GP L.L.C., the general partner of Thru Line L.P.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Aquestive Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NEW JERSEY, 07059

Item 2.

(a)

Name of person filing:

Pursuant to Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Act"), the undersigned hereby files this Schedule 13G Statement on behalf of Edward P. Bass ("EPB") and Thru Line L.P., a Delaware limited partnership ("Thru Line"), all of such persons and entities being referred to herein as the "Reporting Persons." Additionally, information is included herein with respect to Thru Line GP L.L.C., a Delaware limited liability company (the "Controlling Person"). The Reporting Persons and the Controlling Person are sometimes hereinafter collectively referred to as the "Item 2 Persons." The Item 2 Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Act, although neither the fact of this filing nor anything contained herein shall be deemed to be an admission by the Item 2 Persons that such a group exists.

(b)

Address or principal business office or, if none, residence:

The address of the principal business office of each of the Item 2 Persons is 201 Main Street, Suite 3100, Fort Worth, Texas 76102.

(c)

Citizenship:

All of the natural persons listed in Item 2(a) are citizens of the United States of America.

(d)

Title of class of securities:

Common Stock, Par Value $0.001 Per Share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

Reporting Persons EPB Because of his position as the sole director and President of the Controlling Person, which is the general partner of Thru Line, and his ownership of 1,509,294 shares held by him directly, EPB may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of an aggregate of 9,385,561 shares of the Stock. Thru Line The aggregate number of shares of the Stock that Thru Line owns beneficially, pursuant to Rule 13d 3 of the Act, is 7,876,267. Controlling Person Because of its position as the general partner of Thru Line, the Controlling Person may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of 7,876,267 shares of the Stock. To the best of the knowledge of the Reporting Persons, other than as set forth above, none of the persons named in Item 2 herein is the beneficial owner of any shares of the Stock.

(b)

Percent of class:

Reporting Persons EPB EPB may be deemed to be the beneficial owner of approximately 7.5% of the outstanding shares of the Stock. Thru Line Thru Line owns approximately 6.3% of the outstanding shares of the Stock. Controlling Person The Controlling Person may be deemed to be the beneficial owner of approximately 6.3% of the outstanding shares of the Stock. To the best of the knowledge of the Reporting Persons, other than as set forth above, none of the persons named in Item 2 herein is the beneficial owner of any shares of the Stock. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Reporting Persons EPB EPB has the sole power to vote or to direct the vote of an aggregate of 9,385,561 shares of the Stock, including (i) 7,876,267 shares in his capacity as the sole director and President of the Controlling Person, which is the general partner of Thru Line, and (ii) 1,509,294 shares held by him individually. Thru Line Acting through its general partner, Thru Line has the sole power to vote or to direct the vote of 7,876,267 shares of the Stock. Controlling Person In its capacity as the general partner of Thru Line, the Controlling Person has the sole power to vote or to direct the vote of 7,876,267 shares of the Stock.

(ii) Shared power to vote or to direct the vote:

Reporting Persons EPB EPB has no shared power to vote or to direct the vote of any shares of the Stock. Thru Line Thru Line has no shared power to vote or to direct the vote of any shares of the Stock. Controlling Person The Controlling Person has no shared power to vote or to direct the vote of any shares of the Stock.

(iii) Sole power to dispose or to direct the disposition of:

Reporting Persons EPB EPB has the sole power to dispose or to direct the disposition of an aggregate of 9,385,561 shares of the Stock, including (i) 7,876,267 shares in his capacity as the sole director and President of the Controlling Person, which is the general partner of Thru Line, and (ii) 1,509,294 shares held by him individually. Thru Line Acting through its general partner, Thru Line has the sole power to dispose or to direct the disposition of 7,876,267 shares of the Stock. Controlling Person In its capacity as the general partner of Thru Line, the Controlling Person has the sole power to dispose or to direct the disposition of 7,876,267 shares of the Stock.

(iv) Shared power to dispose or to direct the disposition of:

Reporting Persons EPB EPB has no shared power to dispose or to direct the disposition of any shares of the Stock. Thru Line Thru Line has no shared power to dispose or to direct the disposition of any shares of the Stock. Controlling Person The Controlling Person has no shared power to dispose or to direct the disposition of any shares of the Stock.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

This Schedule 13G is being filed on behalf of each of the Item 2 Persons pursuant to Rule 13d-1(c). Consistent with Item 2 of the cover page for each Reporting Person and Item 2(a) of this Schedule 13G, the Item 2 Persons neither affirm nor disclaim the existence of a group among them. The identity of each of the Item 2 Persons is set forth in Item 2(a) hereof.

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bass Edward P

Signature:	/s/ Edward P. Bass
Name/Title:	Self
Date:	10/07/2026

THRU LINE L.P.

Signature:	/s/ Thomas W. White
Name/Title:	Secretary
Date:	10/07/2026

Form SCHEDULE 13G Aquestive Therapeutics, Filed by: Bass Edward P

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed